5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | SELL | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 5.31▼ | 5.30▼ | 5.23▲ | 5.31▼ | 2.44▲ |
MA10 | 5.23▲ | 5.26▲ | 5.29▼ | 5.78▼ | 1.41▲ |
MA20 | 5.32▼ | 5.43▼ | 5.39▼ | 3.22▲ | 0.92▲ |
MA50 | 5.35▼ | 5.43▼ | 5.07▲ | 1.52▲ | 1.12▲ |
MA100 | 5.16▲ | 3.43▲ | 2.86▲ | 1.00▲ | 5.66▼ |
MA200 | 2.89▲ | 2.06▲ | 1.73▲ | 1.17▲ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.003▲ | -0.040▼ | -0.077▼ | 0.142▲ | 0.551▲ |
RSI | 46.214▼ | 49.347▼ | 51.802▲ | 65.934▲ | 85.446▲ |
STOCH | 81.942▲ | 42.008 | 24.654 | 52.393 | 45.334 |
WILL %R | -32.877 | -67.550 | -71.676 | -29.732 | -28.392 |
CCI | 15.653 | -37.883 | -43.551 | 29.765 | 222.437▲ |
Monday, August 11, 2025 12:19 PM
Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company developing targeted therapies to deliver genetic medicines to m ...
|
Friday, August 08, 2025 06:23 PM
The company reported a net loss attributable to common stockholders of $5.7 million, or $1.99 per share, for the three months ended June 30, 2025, compared to a net loss attributable to common ...
|
Friday, August 08, 2025 01:23 PM
The company reported a net loss attributable to common stockholders of $5.7 million, or $1.99 per share, for the three months ended June 30, 2025, compared to a net loss attributable to common ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 5.26 | 5.3863 | 5.0117 | 5.30 | 77,022 |
14/08/25 | 5.77 | 6.0531 | 4.85 | 5.04 | 293,382 |
13/08/25 | 5.07 | 5.996 | 5.07 | 5.86 | 154,700 |
12/08/25 | 5.00 | 5.5099 | 4.99 | 5.29 | 116,328 |
11/08/25 | 5.06 | 5.2406 | 4.75 | 5.04 | 133,381 |
08/08/25 | 5.66 | 5.757 | 5.00 | 5.01 | 164,900 |
07/08/25 | 5.84 | 6.17 | 5.60 | 5.76 | 188,700 |
06/08/25 | 7.13 | 7.13 | 5.90 | 6.18 | 266,600 |
05/08/25 | 6.63 | 7.25 | 5.44 | 7.25 | 318,250 |
04/08/25 | 6.8388 | 7.32 | 6.6768 | 7.1172 | 135,744 |
|
|
||||
|
|
||||
|
|